List of Excipients in Branded Drug STENDRA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Vivus LLC	STENDRA	avanafil	62541-501	CALCIUM CARBONATE
Vivus LLC	STENDRA	avanafil	62541-501	FERRIC OXIDE YELLOW
Vivus LLC	STENDRA	avanafil	62541-501	FUMARIC ACID
Vivus LLC	STENDRA	avanafil	62541-501	HYDROXYPROPYL CELLULOSE
Vivus LLC	STENDRA	avanafil	62541-501	LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE

STENDRA Excipient Strategy and Commercial Opportunities for Avanafil

Last updated: August 22, 2026

STENDRA contains avanafil, a PDE5 inhibitor approved by the FDA for erectile dysfunction. Its commercial formulation is an immediate-release, film-coated tablet using conventional excipients: mannitol, hypromellose, croscarmellose sodium, fumaric acid, magnesium stearate, colloidal silicon dioxide, titanium dioxide, triacetin and yellow ferric oxide.[1] The primary commercial opportunity is not a novel excipient alone. It is a differentiated delivery platform that improves onset, food robustness, tolerability, dose flexibility or manufacturing economics while preserving avanafil exposure.

A generic immediate-release tablet remains the lowest-risk route. More valuable opportunities include orally disintegrating tablets, sublingual or buccal dosage forms, alcohol- and sugar-free products, lactose-free formulations, unit-dose products and low-cost high-throughput manufacturing platforms.

What is STENDRA and which excipients are used?

STENDRA is the brand name for avanafil, an oral selective PDE5 inhibitor. The FDA approved STENDRA in April 2012 under NDA 202276. The marketed strengths are 50 mg, 100 mg and 200 mg tablets.[1]

STENDRA formulation composition

Component	Functional role
Avanafil	Active pharmaceutical ingredient
Mannitol	Diluent and mouthfeel modifier
Hypromellose	Binder and film-forming polymer
Croscarmellose sodium	Superdisintegrant
Fumaric acid	Acidulant and microenvironment pH modifier
Magnesium stearate	Lubricant
Colloidal silicon dioxide	Glidant and flow aid
Titanium dioxide	Opacifier and colorant
Triacetin	Film-coating plasticizer
Yellow ferric oxide	Film-coating colorant

The formulation is designed for rapid disintegration and immediate release rather than extended release. The label permits dosing approximately 15 minutes before sexual activity, subject to the prescribed dose and clinical response.[1]

Why the excipient selection matters

Avanafil products compete in a market where patients value speed, convenience and predictable performance. Excipients affect:

• Tablet disintegration and dissolution.
• Dose uniformity at 50 mg, 100 mg and 200 mg.
• Tablet size and swallowability.
• Sensory attributes, including mouthfeel and grittiness.
• Compression force and tablet robustness.
• Sensitivity to humidity and lubricant overmixing.
• Food-related variability.
• Cost of goods and manufacturing yield.

The current formulation uses standard, widely available excipients. That reduces supply-chain and regulatory risk but leaves room for differentiated products.

What excipient strategies are available for STENDRA generic development?

The strongest near-term strategy is a Q1/Q2-equivalent immediate-release tablet with controlled disintegration and dissolution. A more differentiated strategy uses excipients to create an alternative dosage form that may support a 505(b)(2) pathway or a separate product-positioning strategy.

1. Direct-compression immediate-release tablets

Direct compression is the most commercially practical platform for an avanafil generic. A formulation can retain mannitol, croscarmellose sodium, colloidal silicon dioxide and magnesium stearate while optimizing:

• Particle-size distribution.
• Avanafil-to-diluent ratio.
• Lubrication time.
• Compression force.
• Tablet hardness.
• Disintegration time.
• Dissolution across physiologic pH conditions.

Mannitol is attractive because it provides good mouthfeel and can support smaller, more acceptable tablets than some conventional fillers. The main development risk is segregation if avanafil and excipients have materially different particle sizes or densities.

2. Coprocessed excipients

Coprocessed mannitol-based systems can improve flow, compactibility and tablet consistency. They may reduce the need for multiple excipients and simplify scale-up. The commercial benefit is strongest when the product uses high-speed rotary compression or requires a smaller tablet.

The regulatory value is lower than the manufacturing value. A coprocessed excipient does not by itself create meaningful market exclusivity. Protection would need to arise from a specific composition, process, performance profile or dosage form.

3. Orally disintegrating tablets

An orally disintegrating tablet, or ODT, is the clearest formulation opportunity beyond the reference product. Potential excipient systems include:

• Spray-dried mannitol for rapid wetting and pleasant mouthfeel.
• Crospovidone or croscarmellose sodium as superdisintegrants.
• Low-substitution hydroxypropyl cellulose for binding and rapid breakup.
• Silicified excipients for flow and compactibility.
• Sweeteners and flavors for taste management.
• Ion-exchange resins or polymeric adsorbents for avanafil taste masking.

An ODT could improve convenience for patients who have difficulty swallowing tablets. It could also create a brand extension with a different patient-use profile. The main technical challenge is avanafil’s taste and the need to maintain mechanical strength without slowing disintegration.

FDA ODT guidance emphasizes rapid disintegration, adequate mechanical strength and appropriate in vitro characterization.[2] A product that dissolves in the mouth but is swallowed before meaningful transmucosal absorption should not be marketed as producing sublingual pharmacokinetics without supporting clinical evidence.

4. Sublingual and buccal systems

Sublingual films, buccal films and rapidly dissolving sublingual tablets could target faster perceived onset and improved portability. Candidate excipients include pullulan, hydroxypropyl methylcellulose, polyvinyl alcohol, polyethylene oxide and mucoadhesive polymers.

The opportunity is technically attractive but regulatory risk is higher. A true transmucosal product may require pharmacokinetic and clinical data beyond a conventional ANDA. The formulation must address:

• Avanafil solubility and dose loading.
• Taste and local irritation.
• Residence time.
• Saliva volume and patient technique.
• Dose uniformity in thin films.
• Packaging against moisture.
• Whether absorption is oral-mucosal or gastrointestinal.

A buccal product with a new exposure profile is more likely to require a 505(b)(2) application than a conventional generic pathway.

5. Taste-masked liquid or multiparticulate products

A liquid suspension, orally disintegrating granule or sprinkle formulation could serve patients who cannot swallow tablets. Taste masking may use ion-exchange resins, lipid coating, polymer coating or cyclodextrin complexes.

The commercial market is narrower than for tablets. Avanafil is administered on demand, and a liquid product may create stability, dosing and packaging burdens. The opportunity improves in institutional, telehealth or specialty-pharmacy channels where unit-dose packaging and patient-specific dosing have value.

6. Lactose-free, sugar-free and excipient-reduced formulations

The reference product uses mannitol rather than lactose, which already provides a lactose-free positioning advantage if confirmed in the final product label. A differentiated formulation could also eliminate unnecessary colorants, reduce excipient load or provide a sugar-free ODT.

These changes support commercial messaging and patient tolerability but rarely create strong exclusivity. They are most useful as part of a broader product package involving a new dosage form, improved stability or a manufacturing cost advantage.

How should an avanafil excipient program address food effects?

STENDRA labeling addresses administration with or without food and identifies clinically relevant food-effect information.[1] An excipient strategy should therefore focus on consistent dissolution rather than simply maximizing release speed.

Food-robust formulation design

Development teams should evaluate:

• Dissolution in biorelevant media.
• Fed and fasted pharmacokinetics.
• Tablet disintegration after high-fat meals.
• Surfactant sensitivity.
• Hydrophobic lubricant levels.
• Polymer swelling under fed-state conditions.
• Dose proportionality across 50 mg, 100 mg and 200 mg.

A formulation that releases avanafil rapidly in water but slows materially in fed-state media may offer limited practical differentiation. A strong product would preserve rapid and reproducible exposure across ordinary meal conditions without increasing peak-related adverse effects.

What patent protection can support STENDRA formulation opportunities?

The original avanafil composition and method-of-use patent estate is separate from new excipient protection. Formulation developers should distinguish four categories of intellectual property.

Composition-of-matter and active-ingredient patents

These patents protect avanafil or related chemical entities. They generally create the strongest exclusionary rights but are tied to the active ingredient and cannot be avoided by changing excipients while the claims remain in force.

Formulation patents

Potential claims may cover:

• Specific avanafil-to-excipient ratios.
• Defined disintegration or dissolution profiles.
• Taste-masked particles.
• ODT compositions.
• Buccal or sublingual films.
• Solid dispersions or cyclodextrin complexes.
• Moisture-control packaging combined with a dosage form.
• Stability performance over a defined storage period.

A formulation patent is stronger when it contains structural limitations that competitors cannot easily substitute. Claims based only on a broad list of conventional excipients are vulnerable to design-around and obviousness challenges.

Method-of-use patents

Method-of-use protection may cover dosing regimens, patient populations, timing relative to sexual activity, dose escalation or treatment of selected erectile dysfunction subgroups. A generic applicant may challenge listed method-of-use patents through a Paragraph IV certification or use a Section viii statement that omits the patented indication or method from labeling, depending on the claim scope and FDA listing.

Manufacturing patents

Manufacturing protection can cover:

• Particle engineering.
• Controlled crystallization.
• Granulation conditions.
• Low-shear blending.
• Lubrication control.
• Continuous manufacturing.
• Coating processes.
• Moisture-barrier packaging.

Manufacturing patents are commercially relevant when they lower cost or produce a measurable quality advantage. They are less useful if the process is not detectable in the finished product and can be practiced without infringement risk.

When does STENDRA lose exclusivity and what is the Paragraph IV risk?

STENDRA’s FDA marketing exclusivity and patent protection are separate issues. FDA drug exclusivity depends on the approval pathway and regulatory designation. Patent expiry depends on the specific listed patent, patent-term adjustment and any pediatric extension.

The original STENDRA approval was in 2012. New chemical entity exclusivity generally lasted five years from approval, subject to the applicable statutory framework. That period did not prevent all subsequent competition indefinitely. Generic entry depends on Orange Book-listed patents, certifications, litigation and any settlement terms.

Orange Book and Paragraph IV analysis

A generic avanafil applicant must review the current FDA Orange Book for:

• Listed patent numbers.
• Patent expiration dates.
• Patent-use codes.
• Delisting activity.
• First-filer status.
• Paragraph IV certifications.
• Any 30-month litigation stay.

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable or will not be infringed. The brand holder may sue within 45 days, triggering a potential 30-month stay under the Hatch-Waxman framework.[3]

For a commercial launch model, the relevant dates are:

Event	Commercial significance
NDA approval	Starts applicable regulatory exclusivity periods
Orange Book patent listing	Defines patents requiring certification
ANDA submission	Establishes potential first-filer and review position
Paragraph IV notice	Creates litigation and launch-risk exposure
45-day litigation window	Determines whether a statutory stay may arise
30-month stay	Can delay approval, subject to court and regulatory developments
Patent expiry or settlement date	Determines practical launch timing
FDA tentative approval	Can preserve launch readiness before a blocking patent expires
Final approval	Permits commercial launch if no other barrier remains

An exact current Stendra patent-expiration conclusion requires the live Orange Book record and the applicable patent certificates. The commercial diligence point is clear: a formulation investment should be timed against the earliest legally available generic launch date, not the nominal expiry of the active-ingredient patent alone.

How strong is the STENDRA patent estate for an excipient-driven entrant?

The estate is likely strongest around the active ingredient and approved therapeutic use, and weaker for ordinary excipient substitutions. Conventional changes from one diluent or superdisintegrant to another usually provide limited freedom-to-operate value unless they avoid active patents and produce a separately patentable technical effect.

Relative strength of possible protections

Protection type	Typical strength	Commercial use
Avanafil composition patent	High while valid	Blocks the active ingredient
Broad immediate-release tablet claim	Moderate to low	Vulnerable to invalidity and design-around
Specific ODT composition	Moderate	Supports differentiated product
Taste-masked avanafil particles	Moderate to high if technically narrow	Protects patient-use advantage
Buccal or sublingual delivery system	Moderate	Supports 505(b)(2) product strategy
Manufacturing process	Variable	Can reduce costs or protect quality
Packaging and moisture-control system	Low to moderate	Useful when stability is a material problem

The strongest excipient-led strategy combines a defensible formulation claim with a measurable performance benefit, such as rapid disintegration, improved fed-state dissolution, lower friability or improved stability.

Which companies challenge STENDRA and what is the competitive landscape?

The relevant competitors are not limited to avanafil products. Sildenafil, tadalafil and vardenafil compete in the same PDE5 inhibitor category, with different duration, onset, food-effect and pricing profiles.

Product	Active ingredient	Typical market position
STENDRA	Avanafil	Rapid-onset, on-demand PDE5 inhibitor
Viagra and generics	Sildenafil	Large generic base and broad physician familiarity
Cialis and generics	Tadalafil	Long duration and daily-use positioning
Levitra and generics	Vardenafil	Established PDE5 alternative
OTC or supplement products	Variable	Non-equivalent and regulatory-sensitive substitutes

Generic sildenafil and tadalafil create substantial price pressure. An avanafil entrant cannot depend on active-ingredient novelty alone. It needs a low-cost tablet, a clearly differentiated dosage form or a distribution advantage.

Publicly documented litigation and settlement positions can change as ANDAs are filed and disputes resolve. The relevant parties may include the STENDRA rights holder, generic pharmaceutical companies and contract manufacturers. Current litigation status should be tied to the specific Orange Book patents and federal docket rather than inferred from the product’s approval history.

What FDA pathway is best for a new STENDRA formulation?

A conventional immediate-release avanafil tablet should generally target an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence to the reference product. The product must match the reference in dosage form, strength, route and active ingredient, subject to FDA requirements.

A novel ODT, film, liquid or transmucosal product may require a 505(b)(2) application if it changes dosage form, route, formulation or exposure profile. The 505(b)(2) route can support differentiated labeling but generally requires more clinical and regulatory work.

Regulatory development priorities

A formulation program should establish:

1. Assay and content uniformity.
2. Dissolution across multiple media and pH values.
3. Disintegration and mechanical strength.
4. Impurity and degradation profiles.
5. Photostability and moisture stability.
6. Extractables and leachables for films or specialized packaging.
7. Fed and fasted bioequivalence where required.
8. Comparative adverse-event and tolerability data for materially different exposure profiles.

The reference product’s clinical warnings also constrain excipient-driven innovation. Avanafil labeling includes contraindication information involving nitrates and warnings concerning cardiovascular status, hypotension, priapism, vision and hearing-related events.[1] A formulation that increases peak exposure or accelerates absorption materially could create avoidable safety and regulatory risk.

What commercial opportunities exist for STENDRA excipients?

The most attractive opportunities fall into four categories.

Low-cost generic supply

A standard tablet using high-volume excipients can compete through manufacturing efficiency, reliable supply and low pricing. This is the largest-volume opportunity but also the most exposed to generic competition.

Premium convenience dosage forms

ODTs, sublingual tablets and films can support higher pricing if they offer meaningful patient convenience. Taste masking and packaging are critical cost centers.

Contract development and manufacturing

Excipient suppliers can partner with generic companies to provide:

• Ready-to-use direct-compression blends.
• Mannitol-based ODT platforms.
• Avanafil taste-masking systems.
• Film-forming polymer systems.
• Moisture-barrier unit-dose packaging.
• Formulation and bioequivalence support.

The value proposition is faster development and lower scale-up risk rather than ownership of the active ingredient.

Geographic expansion

A stable, compact tablet or unit-dose ODT can support emerging-market distribution where cold-chain infrastructure is unnecessary. Geographic freedom-to-operate must be assessed country by country because patent terms, regulatory approvals and product registrations differ.

What revenue exposure and launch scenarios apply to STENDRA?

STENDRA revenue is exposed to three variables: brand retention, generic timing and category substitution. Generic entry normally compresses price rapidly, while differentiated formulations can preserve a premium segment.

Launch scenario	Expected commercial effect
Standard avanafil generic	Rapid price competition; volume depends on payer substitution
Authorized generic	Lower litigation risk and controlled brand erosion
ODT generic or 505(b)(2) product	Higher development cost with potential premium pricing
Sublingual or buccal product	Differentiated positioning but higher clinical and regulatory risk
Hospital or specialty formulation	Smaller volume and potentially stronger margins
International launch	Depends on local patents, registration and distribution economics

Revenue estimates should not be based solely on STENDRA brand sales. The addressable market includes the broader PDE5 class, where generic sildenafil and tadalafil may set the practical price ceiling.

Key Takeaways

• STENDRA is an avanafil immediate-release tablet approved by the FDA in 2012.
• Its excipient system uses conventional materials, led by mannitol, hypromellose, croscarmellose sodium, fumaric acid, magnesium stearate and colloidal silicon dioxide.
• The lowest-risk opportunity is a Q1/Q2-equivalent generic tablet optimized for dissolution, content uniformity and manufacturing cost.
• The strongest differentiated opportunities are ODTs, taste-masked products, sublingual systems, buccal films and moisture-protected unit-dose formats.
• Excipient substitution alone usually provides weak patent protection.
• A formulation patent is stronger when it links a defined composition to a measurable technical result.
• ANDA development is suitable for a conventional generic; novel dosage forms may require a 505(b)(2) application.
• Current Orange Book patents, Paragraph IV filings, litigation and settlement terms determine practical generic launch timing.
• Generic sildenafil and tadalafil create substantial pricing pressure and limit the value of an undifferentiated avanafil product.
• Excipient suppliers have the clearest commercial role in ready-to-use tablet platforms, taste masking, ODT systems and contract development support.

FAQs

Can mannitol be replaced in a STENDRA generic?

Yes. A generic applicant can use a different diluent if the finished product meets applicable pharmaceutical-equivalence, quality and bioequivalence requirements. The replacement must preserve tablet performance and may affect patent and formulation freedom to operate.

Does an ODT version of avanafil automatically receive new market exclusivity?

No. A new dosage form may qualify for patent protection or a separate regulatory pathway, but the dosage form alone does not automatically create statutory exclusivity. Eligibility depends on the application type, FDA designations and granted patent claims.

What is the best excipient for avanafil taste masking?

No single excipient is universally optimal. Ion-exchange resins, polymer coatings, lipid barriers and cyclodextrin systems are candidate platforms. The preferred system depends on taste intensity, dose loading, release rate and manufacturability.

Can a buccal avanafil film claim faster onset than STENDRA tablets?

Only if comparative pharmacokinetic or clinical evidence supports the claim. A film may disintegrate rapidly without producing meaningful transmucosal absorption or faster clinical effect.

Are excipient patents useful after avanafil patent expiry?

Yes, if they protect a commercially valuable dosage form, manufacturing process, stability profile or patient-use advantage. Their value depends on claim scope, validity, detectability and the ability to prevent practical design-around.

References

1. U.S. Food and Drug Administration. (2012). STENDRA (avanafil) tablets, prescribing information.
2. U.S. Food and Drug Administration. (2008). Guidance for industry: Orally disintegrating tablets.
3. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book.